An Efficacy, Safety, and Tolerability Study of Veligrotug (VRDN-001), in Participants With Chronic Thyroid Eye Disease (TED) (THRIVE-2)

Exclusion Criteria

• •Must not have received prior treatment with another anti-IGF-1R therapy
• •Must not have received systemic corticosteroids for any condition, including TED, or selenium within 2 weeks prior to first dose
• •Must not have received other immunosuppressive drugs or another investigational agent for any condition, including TED, or any other therapy for TED, within 8 weeks prior to first dose
• •Must not have received radioactive iodine (RAI) treatment within 8 weeks prior to first dose
• •Must not have a pre-existing ophthalmic condition in the study eye that in the opinion of the study doctor would confound interpretation of the study results
• •Must not have had previous orbital irradiation or decompression surgery for TED to the study eye's orbit
• •Must not have inflammatory bowel disease
• •Have abnormal baseline audiometry Pure Tone Average (PTA) assessment or history of significant (as determined by the Investigator) ear pathology, relevant ear surgery or hearing loss.
• •Female TED participants must not be pregnant or lactating